Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-CDI: FMT vs Fidaxomicin vs Vancomycin for CDI
NCT07120490Not yet recruiting
- Sponsor
- Medical University of Warsaw
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Live Biotherapeutic Products
01
Overview
Randomised, open-label trial of Fecal Microbiota Transplantation Capsule in Clostridioides difficile infection (CDI) (3 arms), sponsored by Medical University of Warsaw. Primary endpoint: Recurrence rate of Clostridioides difficile infection (CDI) at 12 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07120490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120490.